ProCE Banner Activity

Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

Podcast Episodes
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss key data on using TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

Released: November 02, 2021

Expiration: November 01, 2022

No longer available for credit.

Share

Faculty

Jean Yves Blay

Jean Yves Blay, MD, PhD

Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France

Robin L. Jones

Robin L. Jones, BSc, MBBS, MRCP, MD (Res)

Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Jean Yves Blay, MD, PhD

Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France

Jean Yves Blay, MD, PhD, has disclosed that he has received funds for research support and consulting fees from Bayer, Blueprint, Deciphera, Novartis, PharmaMar, and Roche.

Robin L. Jones, BSc, MBBS, MRCP, MD (Res)

Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Robin L. Jones, BSc, MBBS, MRCP, MD(Res), has disclosed that he has received consulting fees from Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Daichii, Deciphera, Eisai, Epizyme, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, PharmaMar, Spring Works, SynOx, and Tracon.